Similar articles for PMID: 32859703

Year	Number of Results
1999	1
2002	3
2003	1
2004	9
2005	2
2006	2
2007	1
2008	4
2009	7
2010	11
2011	18
2012	21
2013	26
2014	23
2015	8
2016	13
2017	17
2018	12
2019	20
2020	38
2021	69
2022	89
2023	36
2024	1

1

Multimodal Imaging of 2-Cycle PRRT with ¹⁷⁷Lu-DOTA-JR11 and ¹⁷⁷Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.

Albrecht J, Exner S, Grötzinger C, Prasad S, Konietschke F, Beindorff N, Kühl AA, Prasad V, Brenner W, Koziolek EJ. Albrecht J, et al. J Nucl Med. 2021 Mar;62(3):393-398. doi: 10.2967/jnumed.120.250274. Epub 2020 Aug 28. J Nucl Med. 2021. PMID: 32859703 Free PMC article.

2

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.

Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, de Jong M. Dalm SU, et al. J Nucl Med. 2016 Feb;57(2):260-5. doi: 10.2967/jnumed.115.167007. Epub 2015 Oct 29. J Nucl Med. 2016. PMID: 26514177 Free article.

3

Comparison of ⁶⁸Ga-DOTA-JR11 PET/CT with dosimetric ¹⁷⁷Lu-satoreotide tetraxetan (¹⁷⁷Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.

Krebs S, O'Donoghue JA, Biegel E, Beattie BJ, Reidy D, Lyashchenko SK, Lewis JS, Bodei L, Weber WA, Pandit-Taskar N. Krebs S, et al. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3047-3057. doi: 10.1007/s00259-020-04832-9. Epub 2020 May 6. Eur J Nucl Med Mol Imaging. 2020. PMID: 32378020 Free PMC article. Clinical Trial.

4

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Zhang J, et al. J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653971 Free PMC article. Clinical Trial.

5

SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?

Dalm SU, Haeck J, Doeswijk GN, de Blois E, de Jong M, van Deurzen CHM. Dalm SU, et al. J Nucl Med. 2017 Oct;58(10):1609-1614. doi: 10.2967/jnumed.116.189035. Epub 2017 Apr 27. J Nucl Med. 2017. PMID: 28450563 Free article.

6

Prognostic Value of ¹⁸F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy.

Zhang J, Liu Q, Singh A, Schuchardt C, Kulkarni HR, Baum RP. Zhang J, et al. J Nucl Med. 2020 Nov;61(11):1560-1569. doi: 10.2967/jnumed.119.241414. Epub 2020 Mar 13. J Nucl Med. 2020. PMID: 32169914 Free article.

7

First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.

Baum RP, Zhang J, Schuchardt C, Müller D, Mäcke H. Baum RP, et al. J Nucl Med. 2021 Nov;62(11):1571-1581. doi: 10.2967/jnumed.120.258889. Epub 2021 Mar 5. J Nucl Med. 2021. PMID: 33674401 Free PMC article.

8

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA. Wild D, et al. J Nucl Med. 2014 Aug;55(8):1248-52. doi: 10.2967/jnumed.114.138834. Epub 2014 Jun 24. J Nucl Med. 2014. PMID: 24963127 Free article.

9

Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.

Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, Salaun PY, Kerlan V, Bourhis D, Abgral R. Thuillier P, et al. Clin Nucl Med. 2021 Feb 1;46(2):111-118. doi: 10.1097/RLU.0000000000003412. Clin Nucl Med. 2021. PMID: 33234927

10

Peptide Receptor Radionuclide Therapy with ⁶⁷Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model.

Cullinane C, Jeffery CM, Roselt PD, van Dam EM, Jackson S, Kuan K, Jackson P, Binns D, van Zuylekom J, Harris MJ, Hicks RJ, Donnelly PS. Cullinane C, et al. J Nucl Med. 2020 Dec;61(12):1800-1805. doi: 10.2967/jnumed.120.243543. Epub 2020 May 15. J Nucl Med. 2020. PMID: 32414949 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

356 results

Results by year